JMP Securities Downgrades Cerus (CERS) to Market Underperform
More News related to CERS
- Trading Review for Cerus Corp. Issued by Beacon Equity
- Cerus Corporation Receives FDA Blood Products Advisory Committee Guidance for Proposed INTERCEPT Blood System Phase III Trial Design
- Cerus (CERS) Halted As FDA To Review Proposed Phase III Clinical Trial Design for the INTERCEPT Blood System
- Cerus Corporation Stock Trading Halted; FDA Blood Products Advisory Committee to Review and Discuss Proposed Phase III Clinical Trial Design for the INTERCEPT Blood System
- Cerus (CERS) Misses Q3 EPS by 4c
More News related to Downgrades
- Top 10 News Items 11/30-12/04: Non-Farm Payrolls Much Better-Than-Expected, Comcast to Take 51% Stake in NBC Universal, BofA to Repay $45B in TARP Funds
- Trading Radar for 12/7: Kroger (KR), Pep Boys (PBY), Krispy Kreme (KKD), Casey's General Stores (CASY) Report
- Unusual 11 Mid-Day Movers 12/04: BIG, FLOW, SNV, OCLS Higher; TTWO, ZIOP, VSNT, SWHC Lower
- Notable ETF Movers 12/04: UUP, UNG Up; XME, GDX, GLD, SLV Down
- Notable Analyst Rating Changes 12/04: BAC, SNV, FSLR, AKAM Upgraded; TTWO, SWHC, AKS, NFLX Downgraded
JMP Securities downgrades Cerus (Nasdaq: CERS) from Market Perform to Market Underperform.
Cerus Corporation, a biomedical products company, engages in the development and commercialization of the INTERCEPT Blood System.
Related Categories
DowngradesStocks Mentioned
+0.02Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
